retatrutide dosing study Reta clinical trial data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP CutKilo | Retatrutide - what

So, how do you see that analogy or how does ketogenic therapy fit in light of the enthusiasm around GLP-1s

Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors

GLP-1 Receptor Agonist DDIs GLP-1 receptor agonist drug list: Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), Saxenda (liraglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), Trulicity (dulaglutide), Byetta (exenatide), Bydureon (exenatide) Common DDIs with GLP-1 Receptor Agonists SGLT-2 Inhibitor DDIs SGLT-2 inhibitor drug list: Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin), Seglaro (ertugliflozin) Common DDIs with SGLT-2 Inhibitors Read more: GLP-1s and Fertility This article originally appeared on Endocrinology Advisor References: 1

It is not sold for human consumption, treatment, diagnosis, or personal use

64, e2000149